Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BGB-DXP593 in Healthy Subjects
NCT04532294Phase 1Completed
- Sponsor
- BeiGene
- Start
- Sep 2020
- Primary completion
- Feb 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BGB-DXP593 in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by BeiGene. Primary endpoint: Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs). Started Sep 2020; status: completed.
02
Drugs
BGB-DXP593
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04532294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04532294.